Anidulafungina: nueva equinocandina para el tratamiento de micosis / Anidulafungin: a new echinocandin for the treatment of mycosis
Rev. iberoam. micol
; 25(2): 74-77, 2008.
Article
in Spanish
| IBECS
| ID: ibc-75023
Responsible library:
ES1.1
Localization: BNCS
RESUMEN
Los últimos fármacos antifúngicos introducidos han sido las equinocandinas,que tienen un mecanismo de acción distintivo ya que inhiben la síntesisdel ß-1,3-D-glucano, dañando la pared fúngica sin que las células humanas seafecten ya que no contienen ß-1,3-D-glucano. Dentro de las equinocandinas,anidulafungina es la última en ser introducida comercialmente, habiendo sidoaprobada recientemente por la FDA en EE.UU. para el tratamiento de lacandidemia en enfermos no neutropénicos, abscesos intra-abdominales yperitonitis candidiásica. Igualmente la EMEA, en Europa, ha aprobado su usoen candidiasis invasora en enfermos no neutropénicos y en esofagitiscandidiásica. Sus características le acercan al antifúngico ideal, ya que tieneun amplio espectro, es activo a concentraciones inhibitorias mínimas bajasy es fungicida para Candida. Además es bien tolerado, sin interaccionesfarmacológicas y es activo por vía intravenosa, con vida media larga yauto-biodegradable. Finalmente, anidulafungina ha demostrado una mayoreficacia terapéutica al ser comparada con el tratamiento convencional de lacandidemia, pues a pesar de su mayor coste, el tratamiento conanidulafungina es una estrategia terapéutica que conlleva un ahorroeconómico(AU)
ABSTRACT
The latest antifungal drugs introduced for clinical use are echinocandins;they possess a distinctive mechanism of action based on the inhibition of theß-1,3-D-glucan sintesis, through the damage of the fungal cell wall withoutimpairment of human cells because these do not contain ß-1,3-D-glucan.Among echinocandins, anidulafungin is the last that has received the FDAapproval in the EE.UU. for the treatment of candidemia in non-neutropenicpatients, intra-abdominal abscesses and peritonitis caused by Candida.In Europe, the EMEA has also approved its use for invasive candidiasis innon-neutropenic patients and for candidal esofagitis. The characteristics ofanidulafungin are close to those of the ideal antifungal since it has a widespectrum, is active at low minimal inhibitory concentrations and it is fungicidalfor Candida. In addition, it is well tolerated, has few pharmacologicalinteractions, is active intravenously, has a long half life and isauto-biodegradable. Finally, anidulafungin has shown a higher therapeuticefficiency when compared with the conventional treatment of candidemia,since although it is more expensive, the treatment with anidulafungin is highlycost effective(AU)
Search on Google
Collection:
National databases
/
Spain
Database:
IBECS
Main subject:
Echinocandins
/
Mycoses
/
Antifungal Agents
Limits:
Humans
Language:
Spanish
Journal:
Rev. iberoam. micol
Year:
2008
Document type:
Article
Institution/Affiliation country:
Hospital Universitario 12 de Octubre/España